Lixudebart
立尤德拜单抗
Report date: 2025/03/19 16:56:44
First In Class
Base Information
Drug NameLixudebart
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[12]
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInsermThe Mount Sinai HospitalUniversité de Strasbourg
China Registration ClassN/A
Develop Information
Active CompaniesAlentis Therapeutics AG
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A